Key facts
- This page summarizes Mark E. Saad's Form 4 filing for Axsome Therapeutics, Inc. (AXSM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Mar 2022, 16:00.
Mark E. Saad - 04 Mar 2022 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)
- Reporting relationship
- Director
- Issuer ticker
- AXSM
- Reported as of
- 04 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Mar 2022, 16:00:15 UTC
- Prior SEC filing
- 19 Nov 2021
- Next SEC filing
- 07 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Herriot Tabuteau, M.D., Attorney in Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark E. Saad filed Form 4 for Axsome Therapeutics, Inc. (AXSM) on 08 Mar 2022.
Change
- Previous filing in this sequence was filed on 19 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXSM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +2,337
- Change %
- Price
- $0.000000
- Shares after
- 2,337
- Date
- 04 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,337
- Exercise price
- $29.91
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents 2,337 options elected to be received in lieu of cash compensation earned in 2021. All of such options are immediately exercisable.